Key result
In cancer patients undergoing chemotherapy, positive cardiac troponin I was associated with a significantly higher risk of LVEF decline compared to negative patients (RD 0.279; 95% CI 0.248-0.311; p=0.000).
Why the study?
Cardiac damage is a significant risk of chemotherapy, and the predictive value of cardiac troponin I for chemotherapy-induced cardiotoxicity in cancer patients needed assessment.
Does elevated cardiac troponin I predict chemotherapy-induced cardiotoxicity in cancer patients?
Meta-Analysis (n=2,033)
Does elevated cardiac troponin I predict chemotherapy-induced cardiotoxicity in cancer patients?
Elevated circulating cardiac troponin I is a significant predictor of early chemotherapy-induced cardiotoxicity, including LVEF decline and heart failure, in cancer patients.
Supports troponin I monitoring during chemotherapy; extends prospective cohort evidence for cardiotoxicity risk stratification.
Background Cardiac damage is a significant risk of chemotherapy. Elevated circulating cardiac troponin I was suggested as a marker for early detection of cardiac damage. Objective We aim to assess the predictive value of cardiac troponin I for chemotherapy-induced cardiotoxicity in cancer patients. Methods We searched PubMed, Web of Science, Embase, and CNKI. Nine prospective studies involving 2033 cancer patients (pts) were included in the meta-analysis. Troponin I (TnI) levels in patients who underwent chemotherapy were categorized into cardiac troponin I (cTnI) positive and negative groups based on the cutoff concentrations described in the included studies. The cumulative effects of chemotherapy-induced cardiotoxicity between the cTnI-positive and cTnI-negative patients were represented as a summarized risk difference (RD) value with a 95% confidence interval. Subgroup analysis and sensitivity analysis were employed to address heterogeneities. Stata software (version 12.0) was utilized for the analysis. Results cTnI-positive pts represented significant cardiotoxicity compared to cTnI-negative pts, as a decline in left ventricular ejection fraction (LVEF): RD = 0.279 [95% CI (0.248–0.311), p = 0.000, I 2 = 81.3%, 8 trials], heart failure (HF): RD = 0.117, [95% CI (0.090–0.144), p = 0.000, I 2 = 77.8%, 6 trials], arrhythmias: RD = 0.057 [95% CI (0.028–0.086), p = 0.000, I 2 = 0.0%, 3 trials], and cumulative events: RD = 0.318 [95% CI (0.272–0.364), p = 0.000, I 2 = 73.5%, 3 trials]. No statistically significant difference in cardiac death, acute pulmonary edema, and acute coronary syndromes between cTnI-positive pts and cTnI-negative pts was identified. Conclusions An increase in circulating troponin I serve as a potential biomarker that reflecting the high risk of early cardiotoxicity in cancer patients who have undergone chemotherapy. The presence of intrinsic unadjusted confounding factors in the reports suggests the need for further study to address this question.
No takes yet. Share an insight, caveat, or question.
Yang Liu (2024) conducted a meta-analysis in Cancer patients undergoing chemotherapy (n=2,033). Positive cardiac troponin I (cTnI) vs. Negative cardiac troponin I was evaluated on Decline in left ventricular ejection fraction (LVEF) (RD 0.279, 95% CI 0.248-0.311, p=0.000). In cancer patients undergoing chemotherapy, positive cardiac troponin I was associated with a significantly higher risk of LVEF decline compared to negative patients (RD 0.279; 95% CI 0.248-0.311; p=0.000).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: